ALT
Altimmune IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$510.50M
P/E Ratio
—
EPS
$-0.92
Beta
0.23
52W High
$7.73
52W Low
$2.56
50-Day MA
$3.03
200-Day MA
$3.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.18
PEG Ratio
32.62
About Altimmune Inc
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | 36,000 |
| Gross Profit (TTM) | $-66.05M |
| EBITDA | $-96.10M |
| Operating Margin | -267247.00% |
| Return on Equity | -42.70% |
| Return on Assets | -24.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.18 |
| Price-to-Book | 1.77 |
| Price-to-Sales (TTM) | 14180.41 |
| EV/Revenue | 5723.62 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 420.00% |
| Shares Outstanding | $194.47M |
| Float | $164.20M |
| % Insiders | 0.41% |
| % Institutions | 57.82% |
Historical Volatility
HV 10-Day
42.06%
HV 20-Day
41.85%
HV 30-Day
55.92%
HV 60-Day
65.19%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($16.06 target)
2
Strong Buy6
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026